John Richard Pinion II
Net Worth
Last updated:
What is John Richard Pinion II net worth?
The estimated net worth of Mr. John Richard Pinion II is at least $8,873,557 as of 1 Mar 2024. He owns shares worth $2,669,113 as insider, has earned $1,721,244 from insider trading and has received compensation worth at least $4,483,200 in Ultragenyx Pharmaceutical Inc..
What is the salary of John Richard Pinion II?
Mr. John Richard Pinion II salary is $747,200 per year as Chief Quality Operations Officer & Executive Vice President of Translational Sciences in Ultragenyx Pharmaceutical Inc..
How old is John Richard Pinion II?
Mr. John Richard Pinion II is 59 years old, born in 1966.
What stocks does John Richard Pinion II currently own?
As insider, Mr. John Richard Pinion II owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | Chief Quality Operations Officer & Executive Vice President of Translational Sciences | 89,268 | $29.9 | $2,669,113 |
What does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
John Richard Pinion II insider trading
Ultragenyx Pharmaceutical Inc.
Mr. John Richard Pinion II has made 10 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 4,173 units of RARE stock worth $224,340 on 1 Mar 2024.
The largest trade he's ever made was exercising 6,198 units of RARE stock on 1 Mar 2021. As of 1 Mar 2024 he still owns at least 89,268 units of RARE stock.
Ultragenyx Pharmaceutical key executives
Ultragenyx Pharmaceutical Inc. executives and other stock owners filed with the SEC:
- Dr. Camille L. Bedrosian M.D. (72) Chief Medical Officer & Executive Vice President
- Dr. Emil D. Kakkis M.D., Ph.D. (65) Pres, Chief Executive Officer & Director
- Mr. Erik Harris (55) Executive Vice President & Chief Commercial Officer
- Mr. John Richard Pinion II (59) Chief Quality Operations Officer & Executive Vice President of Translational Sciences
- Ms. Mardi C. Dier (61) Executive Vice President & Chief Financial Officer